Abstract
alpha2-Adrenergic receptor agonists are analgesic agents, and the alpha2-adrenergic agonist clonidine has been used in clinical studies for regional analgesia after intrathecal administration. We review here recent developments concerning the structure activity relationships of a new class of potent alpha2-adrenergic agonists and their use as analgesic agents. The effect of structure upon cardiovascular side effects is also monitored, such as the prolongation of the QT portion of the cardiac action potential.
Keywords: Adrenergic Receptor, Agonists as Analgesics, Imidazoles and Imidazolines, Adrenoceptor Agonists, Catecholamines, Oxazolines
Current Topics in Medicinal Chemistry
Title: Alpha2-Adrenergic Receptor Agonists as Analgesics
Volume: 1 Issue: 3
Author(s): Robert E. Boyd
Affiliation:
Keywords: Adrenergic Receptor, Agonists as Analgesics, Imidazoles and Imidazolines, Adrenoceptor Agonists, Catecholamines, Oxazolines
Abstract: alpha2-Adrenergic receptor agonists are analgesic agents, and the alpha2-adrenergic agonist clonidine has been used in clinical studies for regional analgesia after intrathecal administration. We review here recent developments concerning the structure activity relationships of a new class of potent alpha2-adrenergic agonists and their use as analgesic agents. The effect of structure upon cardiovascular side effects is also monitored, such as the prolongation of the QT portion of the cardiac action potential.
Export Options
About this article
Cite this article as:
Boyd E. Robert, Alpha2-Adrenergic Receptor Agonists as Analgesics, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395182
DOI https://dx.doi.org/10.2174/1568026013395182 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Diabetes Mellitus and Exposure to the Environmental Toxicant Cadmium with an Emphasis on Likely Mechanisms of Action
Current Diabetes Reviews Bone Metabolism and Histomorphometric Changes in Murine Models Treated with Sclerostin Antibody: A Systematic Review
Current Drug Targets Effect of Fibrin-binding Synthetic Oligopeptide on the Healing of Full-thickness Skin Wounds in Streptozotocin-induced Diabetic Rats
Current Pharmaceutical Design Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Pegylated Fluorescent Peptides as Substrates of Proteolytic Enzymes
Protein & Peptide Letters Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Melatonin and Oxidative Stress in the Diabetic State: Clinical Implications and Potential Therapeutic Applications
Current Medicinal Chemistry Planar Bioadhesive Microdevices: A New Technology for Oral Drug Delivery
Current Pharmaceutical Biotechnology The Role of Genetic Polymorphism in the Formation of Arterial Hypertension, Type 2 Diabetes and their Comorbidity
Current Pharmaceutical Design A Mini-review on HER2 Positive Breast Cancer and its Metastasis: Resistance and Treatment Strategies
Current Nanomedicine Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Scaffold-based Drug Delivery for Cartilage Tissue Regeneration
Current Pharmaceutical Design Editorial (Thematic Issue: Cow’s Milk Allergy: Where do we Stand?)
Endocrine, Metabolic & Immune Disorders - Drug Targets A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets